stockrowQIAGEN N.V.
QGEN Healthcare Diagnostics & Research
QIAGEN N.V.’s revenue for fiscal 2025 (year ended December 2025) was $2.1 billion, up 5.65% from fiscal 2024.
- Revenue
- +0.28%
- EPS
- +7.94%
- Free cash flow
- +30.5%
- Total debt
- +13.8%
Quarter to June 2026, against a year earlier
Follow QGEN
Alert me
QIAGEN N.V. (QGEN) EV/Sales
As of 5 November 2026, QIAGEN N.V. (QGEN) trades at a EV/Sales of 5.4×. Over the past ten years it has ranged from 3.9× (May 2026) to 7.9× (August 2020); the current reading is higher than 45% of that period. That is in line with the Diagnostics & Research industry median of 5.2× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.4× | (2.18%) |
| FY2024 | 5.5× | (1.02%) |
| FY2023 | 5.6× | (1.30%) |
| FY2022 | 5.7× | (5.65%) |
| FY2021 | 6.0× | (15.25%) |
| FY2020 | 7.1× | 27.43% |
| FY2019 | 5.6× | (1.38%) |
| FY2018 | 5.6× | 1.55% |
| FY2017 | 5.6× | 7.83% |
| FY2016 | 5.2× | (3.28%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.2× | (8.95%) |
| Mar 2026 | 4.7× | (14.03%) |
| Dec 2025 | 5.4× | 10.93% |
| Sep 2025 | 4.9× | (12.89%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ICLR ICON PLC compare | 2.4× |
| RDNT RadNet, Inc. compare | 3.0× |
| CRL Charles River Laboratories International, Inc. compare | 4.3× |
| QGEN QIAGEN N.V. | 5.4× |
| MEDP Medpace Holdings, Inc. compare | 6.0× |
| RVTY Revvity Inc. compare | 6.6× |
| BLLN BillionToOne, Inc. compare | 11.0× |
| GH Guardant Health, Inc. compare | 16.6× |
| GRAL GRAIL, Inc. compare | 29.8× |
| Diagnostics & Research industry median | 5.2× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on QGEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement